Phase 3CompletedAge-related condition
Efficacy and Safety of Testogel® in Men With Partial Androgen Deficiency of Aging Males (PADAM)
Multicenter, Double Blind, Randomized, Placebo Controlled Study of Testogel® (Testosterone 50-100mg) to Evaluate Its Efficacy and Safety in Men Presenting With Typical Symptoms of Partial Androgen Deficiency of Aging Males (PADAM) Over a Period of 6 Months With 12 Months Open Label Follow-up
- Sponsor
- Bayer (Industry)
- Enrollment
- 363 enrolled
- Conditions
- Androgens (Deficiency); Male
- Interventions
- Testogel (Testosterone, BAYV001915); Placebo
- Ages
- adults, older adults
- Registry
- NCT00185198, EUCTR2004-001545-15
Full record on ClinicalTrials.gov
From the registry
The purpose of this study is to investigate the effect of a testosterone replacement therapy called Testogel in men with PADAM. The effects on body composition (lean, fat and bone) and other symptoms of PADAM and safety will be studied.
Primary outcomes
- Lean body mass at 6 months
History
Last registry update
Study completion
Primary completion
Registered
Started